logo
You usually need more than a few drops of blood, saliva or urine to detect illnesses. Here's why

You usually need more than a few drops of blood, saliva or urine to detect illnesses. Here's why

Time of India19-05-2025
Melbourne: In the 2000s, biotech company Theranos promised to revolutionise
blood testing
. Founder
Elizabeth Holmes
claimed Theranos technology could perform hundreds of tests using just a finger-prick drop of blood.
If true, their diagnostics would be faster, cheaper and more accessible. Theranos raised hundreds of millions of dollars from investors and was valued at more than USD 9 billion in 2015.
However, the technology never worked, leading to one of the biggest scandals in biotech history. Theranos was secretly using traditional machines to run many tests, then claiming the results came from its own (non-functional) device.
Holmes was eventually convicted of fraud and sentenced to 11 years in prison.
Today, a new startup, Haemanthus, claims to have developed a similar technology. Co-founded by Billy Evans (Holmes' partner), this new company says it can detect and diagnose illnesses using tiny amounts of blood, urine, or even saliva.
While technology has advanced since Theranos' time, it's important to consider these claims carefully.
Clinicians and lab techs can currently detect many conditions with blood, and some with urine or saliva. These are important tools in modern medicine. However, the volumes required are usually much greater than a few drops or a dab.
What can blood detect?
Blood circulates through all organs, transporting cells, nutrients, hormones and waste products. Blood tests collect several millilitres of blood from a vein and send this to a laboratory for analysis.
Blood tests can check if a person has signs of infection or disease, to monitor organ function, or to show how a person is responding to medical treatment. Blood tests are widely used to monitor heart disease, diabetes, kidney disease, or deficiencies in iron or vitamins.
A significant proportion of medical decisions are based on laboratory analysis of blood tests. Making them more affordable and accessible would have great benefits.
What about urine?
Urine is produced by the kidneys and contains waste filtered from the blood. The colour and composition of urine gives you a snapshot of any problems the body might be trying to fix.
Urine analysis
can detect urinary tract infections, kidney disorders, diabetes and liver diseases by measuring sugars, proteins and cells.
As urine tests are non-invasive and easy to administer, they can be used to quickly screen for some conditions.
However, factors such as how much you've had to drink and what you've eaten can influence urine composition, potentially affecting test results.
Saliva can also be used for diagnoses
Saliva is the clear, watery liquid produced by salivary glands in the mouth. It's mostly water (around 99 per cent), but also contains various substances such as hormones, antibodies, enzymes, DNA, RNA and metabolites.
Saliva testing is already used in clinical settings to detect HIV antibodies, monitor levels of cortisol (a marker of stress) and to diagnose viral infections such as COVID.
The potential of saliva as another non-invasive diagnostic tool is growing, especially as researchers identify more markers of disease that it can contain.
However, saliva production varies between individuals. The composition of saliva can be impacted by what you eat and drink, the time of day, or even stress. These variations can limit how consistent and reliable saliva can be for making a diagnosis.
But how much of it do you need?
While diagnosing diseases using bodily fluids isn't new, Haemanthus and other startups differentiate themselves by aiming (and claiming) to need only small amounts for multiple tests: a drop of blood, a swab of saliva, or a few milliliters of urine. This would mean faster, cheaper, more convenient tests that cause less discomfort.
But there are physical limitations of small samples. Many diagnostic markers (called biomarkers) are only present in very low amounts in our body fluids.
When the sample amount decreases, so do the amounts of the biomarkers, making it harder to detect them reliably. This is particularly true for biomarkers such as hormones, cancer markers, or early-stage disease indicators.
What can you detect with a few drops?
Of course, some conditions can be diagnosed using small samples, but generally only one condition is tested for with each small sample, unlike the claims of companies like Theranos.
Finger-prick blood samples, for example, can monitor blood glucose levels of people with diabetes.
Small urine samples can detect urinary tract infections, but not all types of infections at once.
The specific biomarkers for these conditions can be reliably detectable in small amounts of fluid.
To diagnose more complex conditions, or even unknown conditions, multiple tests may be required, each needing different sample preparations. This requires both volume and precision - two things tests with small sample volumes struggle to deliver.
What happens next?
While the idea of diagnosing illnesses with small fluid samples is promising, especially for remote or resource-limited settings, the science suggests we should be cautious.
Most human diseases are complicated, and we usually need comprehensive testing approaches to diagnose them. Relying only on small fluid samples could lead to misdiagnosis, delayed treatments, or unnecessary interventions.
Innovations in biosensor technology, machine learning algorithms and biomarker discovery continue to advance the field. And one day, fast and reliable small volume testing may be possible.
However, a lot more peer-reviewed research and regulatory approvals will be essential to ensure patient safety and diagnostic accuracy.
(The Conversation)
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cohance Lifesciences announces USD 10 mn investment in US-based arm
Cohance Lifesciences announces USD 10 mn investment in US-based arm

News18

time21 minutes ago

  • News18

Cohance Lifesciences announces USD 10 mn investment in US-based arm

New Delhi, Aug 12 (PTI) Cohance Lifesciences on Tuesday announced a strategic investment of USD 10 million (around Rs 87.6 crore) to expand bioconjugation capabilities at its US-based subsidiary, NJ Bio. The investment advances Cohance's global expansion in niche technology-led modalities, enhancing its ability to support innovators from early development through late-phase clinical supply, the company said in a statement. The common good manufacturing practices (cGMP) compliant bioconjugation suite at NJ Bio's Princeton, New Jersey, facility significantly strengthens the company's capabilities to deliver fully integrated Antibody-Drug Conjugate (ADC) solutions, it added. 'The investment … strengthening our footprint in the rapidly growing ADC space. By integrating payload-linker development and bioconjugation capabilities under one roof, NJ Bio will be well-positioned to support accelerated development timelines and help bring life-saving therapies to patients faster," Vivek Sharma, Executive Chairman, Cohance Lifesciences, said. In a separate statement, Cohance announced a Rs 23 crore investment and significant progress on its new oligonucleotide building block manufacturing facility in Hyderabad. 'Together, these investments form part of Cohance's planned capacity expansion program across high-growth modalities, enhancing its ability to serve global innovators from early development to commercial supply," the company said. Cohance Lifesciences, formerly Suven Pharmaceuticals, is an innovator-focused global Contract Research, Development, and Manufacturing Organization (CRDMO), formed through the merger of Cohance Life Sciences into Suven Pharmaceuticals. PTI MSS MR view comments First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

COVID wave is moving across USA: Health experts warn parents that children must do this
COVID wave is moving across USA: Health experts warn parents that children must do this

Economic Times

time2 hours ago

  • Economic Times

COVID wave is moving across USA: Health experts warn parents that children must do this

Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads FAQs Tired of too many ads? Remove Ads United States of America is witnessing a late-summer COVID wave, even as children are preparing to return to school. Fortunately, hospitalization rates remain low. The risk of severe illness and hospitalization among children younger than 1 who are infected with the coronavirus is comparable to that among adults 65 and older. That's why experts have said that a child's first exposure should be through a vaccine, rather than infection. However, this fall, it may not be possible for many parents to have a healthy child younger than age 5 immunized against COVID, as per a health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the CDC, NYT News Service reported. Pfizer 's vaccine has long been available to these children under so-called emergency use authorization. But the Food and Drug Administration is considering discontinuing the authorization for that age group, according to an email sent by the Centers for Disease Control and Prevention to state and local health confirmed the possibility Monday evening and said that the company was "currently in discussions with the agency on potential paths forward." For children 5 to 11 years old, the Pfizer vaccine is expected to be approved and available, according to the CDC's email, which was reviewed by The New York July, the FDA granted full approval to Moderna's COVID vaccine for children -- but only for those who have health conditions that may put them at increased risk should they become infected. Novavax's COVID vaccine has never been available for children younger than upshot is that if the FDA does not renew Pfizer's authorization for children 6 months to 4 years, or fully approve the vaccine, healthy children in that age group will have no officially sanctioned options -- although doctors may still choose to provide the vaccine "off label."In May, Health Security Robert F. Kennedy Jr. announced that COVID vaccines would no longer be offered to healthy children or pregnant women. Kennedy has called the Pfizer and Moderna vaccines dangerous. In May 2021, in the thick of the pandemic, he filed a petition with the FDA demanding that the agency revoke authorization for the CDC, which typically makes such recommendations, later walked back the secretary's statement, saying that healthy children could get the shot if a doctor agreed that it was told the CDC it was ramping up supplies of its vaccine for the fall, according to the agency's email. But it is not approved for healthy children, and if the FDA rescinds authorization for children younger than 5, parents of healthy children will find themselves with no Nixon, a spokesperson for the Department of Health and Human Services, declined to comment on potential regulatory changes and said any reports before an official statement should be treated as "speculation."But public health experts noted that the coronavirus is still a threat, even for otherwise healthy children younger than 2. Among children ages 6 months to 2 years who were hospitalized with COVID from October 2022 to April 2024, more than half had no underlying medical conditions, according to data from the vaccines have also been shown to offer modest protection against long COVID in some children. The effects are already becoming apparent. Providers have stopped ordering last year's shot, as they often do at this time of the year. Normally by this point, there would be a clear plan for the 2025-26 season.A1. The full form of CDC is Centers for Disease Control and Prevention.A2. Full form of FDA is Food and Drug Administration.

Maharashtra reports two new COVID-19 cases
Maharashtra reports two new COVID-19 cases

News18

time2 hours ago

  • News18

Maharashtra reports two new COVID-19 cases

Agency: PTI Last Updated: Mumbai, Aug 12 (PTI) Maharashtra on Tuesday reported two new cases, taking the tally of infections to 2,755 since January this year, the state public health department stated. As many as 44 patients have succumbed to the ailment since the beginning of the year, out of which 43 were suffering from comorbidities and 1 with another disease, it said. Mumbai and Navi Mumbai have recorded one new case each. According to the health department, 45,057 COVID-19 tests were conducted across the state since January 1, and 2,684 patients have recovered to date. Mumbai has recorded 1,106 infections, including 551 in June, 102 in July, and 12 in August so far this year. PTI SM ARU First Published: Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store